Install
Diseases & Conditions
From acute infections to chronic and rare diseases—risk factors, management, and breakthroughs.
- 5 Subtopics
- 9 Tracked terms
- Last 30 days Feed window
Inside Diseases & Conditions
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
- Fitness
- Wellness
- Mental Health
- Nutrition & Diet
- Medical
- Clinical Specialties & Body Systems
- Pharmaceuticals & Biotech
- Public Health & Policy
- Health Tech & Digital Health
- Preventive Care & Screening
- Sexual & Reproductive Health
- Family & Life Stages
- Environmental & Occupational Health
- Insurance, Access & Costs
- Patient Safety & Quality
- Medical Education & Careers
- Travel Health
- Complementary & Integrative Health
- Women's Health
- Men's Health
Latest in Diseases & Conditions
Coalition of Skin Diseases and NCSP groups coalition sign on and support
12+ hour, 24+ min ago (371+ words) Review your profile in our search tool for the public, which helps patients find board-certified dermatologists. Make sure your contact info is up to date in our directory. This listing is for AAD members only. Explore the Academy's new and…...
Cancer Drug Shortages Continue With No Immediate Path Toward Relief
1+ hour, 7+ min ago (31+ words) All responding NCCN members reported shortages, priorities identified but solutions still needed...
Photodynamic Therapy for the Most Common Skin Cancer Wins Approval
33+ min ago (13+ words) Approach for superficial basal cell carcinoma may be ideal for cosmetically sensitive locations...
Ataraxis AI Publishes Landmark Studies Showing Causal AI Predicts Chemotherapy Benefit in Multiple Solid Tumors
13+ hour, 24+ min ago (324+ words) NEW YORK, September 14, 2026--(BUSINESS WIRE)--Ataraxis AI, a company building clinical AI tools to personalize cancer care, today announced scientific breakthroughs and validation results of Ataraxis's AI models. Ataraxis developed breakthrough causal AI methods that learn from large-scale, longitudinal data…...
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
11+ hour, 43+ min ago (474+ words) As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street. Akeso and Summit Therapeutics’ experimental dual-acting cancer drug helped people with lung cancer live about eight months…...
Conducting Oncology Studies Within Poland???s Clinical Research Network
4+ hour, 53+ min ago (272+ words) For this reason, feasibility for clinical trials in Poland should include direct assessment of prospective centers rather than relying exclusively on epidemiological estimates. Discussions with investigators can clarify how many potentially eligible patients are actually seen at a site and…...
Feinstein Institutes Awarded $8.9M for Care Planning Program in Older Adults and Those With Dementia - AOL
15+ hour, 24+ min ago (194+ words) Edith Burns, MD, professor in the Institute of Health System Science at the Feinstein Institutes. “This funding is critical to ensure older adults and patients with dementia receive care aligned with their values,” said Dr. Burns. “Through engaging video education…...
Scholar Rock Drug Wins First-in-Class Approval in Rare Neuromuscular Disease
1+ hour, 57+ min ago (308+ words) Scholar Rock’s Isembyld isn’t the only FDA-approved therapy for spinal muscular atrophy, but it is the first one that directly targets muscle tissue. Isembyld is the first commercial product for Scholar Rock, which is also evaluating the antibody in other…...
Why Katherine LaNasa Was 'Stunned' Walking on Set at 'The Pitt' After Breast Cancer Treatment
1+ hour, 39+ min ago (346+ words) Katherine LaNasa is taking her real-life medical journey and channeling it directly into her work. The 59-year-old actress plays charge nurse Dana Evans on the HBO Max medical drama The Pitt, a role that recently earned her an Emmy in…...
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
21+ hour, 24+ min ago (302+ words) Topline overall survival data expected as early as end of 2026 "Achieving target enrollment in TEBE-AM is an important milestone for Immunocore and a critical step toward addressing the substantial unmet need in previously treated, post-PD1 advanced melanoma, a setting with…...